CURRENT MEDICAL DIAGNOSIS AND
TREATMENT 2026
65TH EDITION
Author(s)Maxine A. Papadakis; Michael
W. Rabow; Kenneth R. McQuaid; Paul L.
Nadler; Erika Leemann Price
TEST BANK
1
Reference: Ch. — Disease Prevention & Health Promotion —
Adult Immunizations (Influenza)
Stem: A 68-year-old man with well-controlled COPD presents in
October for routine care. He asks whether he needs influenza
vaccination this year and whether a high-dose or standard
vaccine is preferable. He has no prior severe vaccine reactions.
Which is the best recommendation?
A. Skip influenza vaccine because COPD patients have limited
,vaccine benefit.
B. Give standard inactivated influenza vaccine (IIV) — high-dose
offers no proven benefit in COPD.
C. Give high-dose inactivated influenza vaccine (IIV-HD) this
season.
D. Give live attenuated influenza vaccine (LAIV) intranasally.
Correct answer: C
Rationale — Correct (C): Adults ≥65 years derive greater
protection from high-dose inactivated influenza vaccine; COPD
increases risk of complications, so IIV-HD is recommended
when available. High-dose formulations produce higher
antibody responses and lower influenza-related hospitalization
in older adults, aligning with CMDT prevention guidance.
Rationale — Incorrect (A): COPD increases, not decreases,
benefit from influenza vaccination due to higher complication
risk.
Rationale — Incorrect (B): Standard IIV is acceptable if high-
dose unavailable, but in ≥65 high-dose is preferred per
evidence.
Rationale — Incorrect (D): LAIV is generally not recommended
for older adults and for those with chronic cardiopulmonary
disease.
Teaching point: Give high-dose inactivated influenza vaccine to
adults ≥65, especially with chronic lung disease.
Citation: Papadakis, M. A., McPhee, S. J., & Rabow, M. W.
,(2026). Current Medical Diagnosis & Treatment (65th ed.). Ch.
Disease Prevention & Health Promotion.
2
Reference: Ch. — Disease Prevention & Health Promotion —
Cervical Cancer Screening
Stem: A 35-year-old woman with no prior abnormal cervical
cytology presents for preventive care. She has never received
HPV vaccination. Which is the recommended next step?
A. Begin Pap testing at age 40; defer until then.
B. Screen now with primary HPV testing alone every 5 years.
C. Perform cytology (Pap) alone every 3 years.
D. No screening necessary until after HPV vaccination series
completed.
Correct answer: B
Rationale — Correct (B): For women 30–65, primary HPV
testing every 5 years is an accepted screening strategy and
provides high sensitivity for CIN2+. At age 35, primary HPV
testing is appropriate even without prior vaccination. This aligns
with contemporary CMDT screening approaches favoring HPV-
based strategies.
Rationale — Incorrect (A): Screening should begin earlier;
delaying until 40 misses standard recommendations.
Rationale — Incorrect (C): Cytology alone every 3 years remains
acceptable but HPV primary testing every 5 years is preferred
, for many patients.
Rationale — Incorrect (D): Vaccination status does not defer
the need for screening in this age group.
Teaching point: Primary HPV testing every 5 years is an
appropriate screening option for women 30–65.
Citation: Papadakis, M. A., McPhee, S. J., & Rabow, M. W.
(2026). Current Medical Diagnosis & Treatment (65th ed.). Ch.
Disease Prevention & Health Promotion.
3
Reference: Ch. — Disease Prevention & Health Promotion —
Colorectal Cancer Screening
Stem: A 52-year-old man with no symptoms and no family
history of colorectal cancer asks which screening test you
recommend. He prefers less invasive testing but wants reliable
results. His last colonoscopy was never done. What is best?
A. No screening until age 60.
B. Annual fecal immunochemical test (FIT) or stool DNA testing
per recommended interval.
C. Flexible sigmoidoscopy only, once at age 55.
D. Immediate barium enema.
Correct answer: B
Rationale — Correct (B): Screening should begin at age 45–50
(depending on guideline) and options include annual FIT or
stool DNA testing at recommended intervals; FIT is noninvasive
TREATMENT 2026
65TH EDITION
Author(s)Maxine A. Papadakis; Michael
W. Rabow; Kenneth R. McQuaid; Paul L.
Nadler; Erika Leemann Price
TEST BANK
1
Reference: Ch. — Disease Prevention & Health Promotion —
Adult Immunizations (Influenza)
Stem: A 68-year-old man with well-controlled COPD presents in
October for routine care. He asks whether he needs influenza
vaccination this year and whether a high-dose or standard
vaccine is preferable. He has no prior severe vaccine reactions.
Which is the best recommendation?
A. Skip influenza vaccine because COPD patients have limited
,vaccine benefit.
B. Give standard inactivated influenza vaccine (IIV) — high-dose
offers no proven benefit in COPD.
C. Give high-dose inactivated influenza vaccine (IIV-HD) this
season.
D. Give live attenuated influenza vaccine (LAIV) intranasally.
Correct answer: C
Rationale — Correct (C): Adults ≥65 years derive greater
protection from high-dose inactivated influenza vaccine; COPD
increases risk of complications, so IIV-HD is recommended
when available. High-dose formulations produce higher
antibody responses and lower influenza-related hospitalization
in older adults, aligning with CMDT prevention guidance.
Rationale — Incorrect (A): COPD increases, not decreases,
benefit from influenza vaccination due to higher complication
risk.
Rationale — Incorrect (B): Standard IIV is acceptable if high-
dose unavailable, but in ≥65 high-dose is preferred per
evidence.
Rationale — Incorrect (D): LAIV is generally not recommended
for older adults and for those with chronic cardiopulmonary
disease.
Teaching point: Give high-dose inactivated influenza vaccine to
adults ≥65, especially with chronic lung disease.
Citation: Papadakis, M. A., McPhee, S. J., & Rabow, M. W.
,(2026). Current Medical Diagnosis & Treatment (65th ed.). Ch.
Disease Prevention & Health Promotion.
2
Reference: Ch. — Disease Prevention & Health Promotion —
Cervical Cancer Screening
Stem: A 35-year-old woman with no prior abnormal cervical
cytology presents for preventive care. She has never received
HPV vaccination. Which is the recommended next step?
A. Begin Pap testing at age 40; defer until then.
B. Screen now with primary HPV testing alone every 5 years.
C. Perform cytology (Pap) alone every 3 years.
D. No screening necessary until after HPV vaccination series
completed.
Correct answer: B
Rationale — Correct (B): For women 30–65, primary HPV
testing every 5 years is an accepted screening strategy and
provides high sensitivity for CIN2+. At age 35, primary HPV
testing is appropriate even without prior vaccination. This aligns
with contemporary CMDT screening approaches favoring HPV-
based strategies.
Rationale — Incorrect (A): Screening should begin earlier;
delaying until 40 misses standard recommendations.
Rationale — Incorrect (C): Cytology alone every 3 years remains
acceptable but HPV primary testing every 5 years is preferred
, for many patients.
Rationale — Incorrect (D): Vaccination status does not defer
the need for screening in this age group.
Teaching point: Primary HPV testing every 5 years is an
appropriate screening option for women 30–65.
Citation: Papadakis, M. A., McPhee, S. J., & Rabow, M. W.
(2026). Current Medical Diagnosis & Treatment (65th ed.). Ch.
Disease Prevention & Health Promotion.
3
Reference: Ch. — Disease Prevention & Health Promotion —
Colorectal Cancer Screening
Stem: A 52-year-old man with no symptoms and no family
history of colorectal cancer asks which screening test you
recommend. He prefers less invasive testing but wants reliable
results. His last colonoscopy was never done. What is best?
A. No screening until age 60.
B. Annual fecal immunochemical test (FIT) or stool DNA testing
per recommended interval.
C. Flexible sigmoidoscopy only, once at age 55.
D. Immediate barium enema.
Correct answer: B
Rationale — Correct (B): Screening should begin at age 45–50
(depending on guideline) and options include annual FIT or
stool DNA testing at recommended intervals; FIT is noninvasive
